Cargando…
Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
INTRODUCTION: Most trials investigating new drugs around the world, including phase I trials, are conducted in outpatient clinics. However, in Japan, regulatory authority requirements and traditional domestic guidelines often require hospitalization of phase I study participants. PATIENTS AND METHOD...
Autores principales: | Shimomura, Akihiko, Kondo, Shunsuke, Kobayashi, Noriko, Iwasa, Satoru, Kitano, Shigehisa, Tamura, Kenji, Fujiwara, Yutaka, Yamamoto, Noboru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533862/ https://www.ncbi.nlm.nih.gov/pubmed/28293794 http://dx.doi.org/10.1007/s10147-017-1108-z |
Ejemplares similares
-
First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021) -
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019) -
First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
por: Koyama, Takafumi, et al.
Publicado: (2020) -
First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2)
receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022) -
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
por: Kitano, Shigehisa, et al.
Publicado: (2020)